---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-113591"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:56:42.306712+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics reports Q3 net loss of $6.7M; updates on Alzheimer’s and DLB trials

## Summary
- Net loss of $6.7M ($0.22 per share) in Q3 2023 vs $6.6M ($0.29 per share) in Q3 2022.
- Cash and equivalents $33.0M; total grant funds $74.3M from NIA; cash runway through Nov 2024.
- Phase 2 SHINE Alzheimer’s topline results expected mid-2024; SHIMMER DLB data also mid-2024.
- START trial initiated allowing lecanemab combo therapy; MAGNIFY dry AMD study dosing started.
- R&D expenses $11.7M (up 41% YoY); G&A $3.1M (down 30% YoY).

## SEC filing metadata
- accession: 0001104659-23-113591
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465923113591/0001104659-23-113591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465923113591/tm2329528d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-113591
- JSON: https://secwatch.observer/filing/0001104659-23-113591.json
- Plain text: https://secwatch.observer/filing/0001104659-23-113591.txt

## Key facts
- Earnings Releases
  COGNITION THERAPEUTICS INC reported third quarter ended September 30, 2023 results: net income net loss of $6.7 million, EPS $(0.22) per basic and diluted share.
  - Period: third quarter ended September 30, 2023
  - Net income: net loss of $6.7 million
  - EPS: $(0.22) per basic and diluted share
  - Result: reported results
  source text: The Company reported a net loss of $6.7 million or $(0.22) per basic and diluted share for the third quarter ended September 30, 2023, compared to a net loss of $6.6 million or $(0.29) per basic and diluted share during the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465923113591/0001104659-23-113591-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.